Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5565119 | 0.94 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5561496 | 0.90 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5563915 | 0.84 | ADORA2A (0.66) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5559771 | 0.84 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5558477 | 0.83 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5559889 | 0.83 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5560059 | 0.83 | ADORA2A (0.75) | ADORA2AADORA1ADORA2BADORA3MEN1 | |
| SCHEMBL5562254 | 0.83 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5566093 | 0.83 | ADORA2A (0.59) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL5563861 | 0.82 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BADORA3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273865-B2 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1670805-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005028484-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065151-A1 | Thiazolopyridine | HOFFMANN-LA ROCHE INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065151-A1 | Thiazolopyridine | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.